Zirconium Zr 89 Bevacizumab

Preferred Label : Zirconium Zr 89 Bevacizumab;

NCIt synonyms : 89Zr-Bevacizumab;

NCIt related terms : BEVACIZUMAB ZIRCONIUM ZR-89;

NCIt definition : A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium Zr 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89 bevacizumab targets and binds to the extracellular domain of the vascular endothelial growth factor receptor (VEGFR). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), allowing the imaging and quantification of VEGFR-expressing tumor cells. VEGFR, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.;

UNII : B552L536ZL;

Détails

Origin ID

C82656;

UMLS CUI

C2826356;

Currated CISMeF NLP mapping
- 89Zr-bevacizumab [MeSH concept]
- 89Zr-bevacizumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- 89Zr-bevacizumab [MeSH concept]
- 89Zr-bevacizumab [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients